Prota Therapeutics, the developer of oral immunotherapies to treat food allergies, has partnered with Chr. Hansen. The partnership will assess the world’s best documented probiotic strain, LGG®, in a Phase III clinical trial to develop a treatment for peanut allergy.
As the conversion wave from synthetic to natural colors continues to rise in the US market, Chr. Hansen gears up for the future
Pocket size, NIR spectrometer transforms feed analysis by enabling real-time, on-farm forage analysis - Chr. Hansen equips their nutritionists and distributors first, followed by all customers.
Jørgen Erichsen, Executive Vice President of the Natural Colors Division, will leave the position as Executive Vice President effective today, 2 February 2018.
EVP Christoffer Lorenzen has been appointed member of the Executive Board of Chr. Hansen Holding A/S.
Refresh and revitalize your beverage brands with these new, improved functionality, color solutions
Chr. Hansen launches culture solution for kids’ drinking yogurt with the probiotic strain L. rhamnosus, LGG®
Five new solutions from Chr. Hansen that can be blended into almost any shade.
With Chr. Hansen’s second generation FreshQ®, more dairies can rely on natural freshness and contribute to reducing food waste
New report documents how 81% of Chr. Hansen’s gross revenue directly supports the UN Global Goals for Sustainable Development
- Delivering on operational and strategic priorities while continuing to build long-term growth
Bring the mild, fresh taste and smooth texture from yogurt into plant based alternatives. Chr. Hansen’s new milk-free cultures do the trick!
GalliPro® Fit is a uniquely formulated probiotic combining three novel strains into one product, creating a 3-in-1 solution for some of the poultry industry’s biggest challenges.
Chr. Hansen launches the widest range of oil soluble, naturally-sourced colors for the North American market.
Research on the human microbiome has exploded in recent years revealing it to be of major importance for human health and disease, creating opportunities for development of next generation probiotics. That is why Chr. Hansen is proud to announce that we have now expanded our world class strain library of potential microbiome modulating strains.
Research confirming the effective in vitro inhibition of the growth of E. coli will be showcased at the Congress on Gastrointestinal Function, where other central studies with livestock and poultry species for food production and biomedical research, as well as clinical and nutritional studies relevant to improving human health and well-being will be presented.
Chr. Hansen realizes strong organic revenue growth of 10% in the first half of 2016/17. With this solid performance in the first half year, we are well positioned to deliver on our ambitions for the year.
New research confirms hatch-to-market benefits of probiotics in poultry production.
Chr. Hansen has had a good start to the year with strong organic revenue growth of 11% in Q1 2016/17, which is better than initially expected for the quarter. Revenue reached EUR 242 million – 13% above last year.
After more than 25 years with Chr. Hansen and 11 years in Executive Management, Knud Vindfeldt will step down from the Executive Board of Chr. Hansen Holding A/S on 28 February 2017.